Moneycontrol PRO
Black Friday Sale
Black Friday Sale
HomeNewsBusinessTale of two companies: Airbus recovers as Boeing reels

Tale of two companies: Airbus recovers as Boeing reels

But while Airbus has returned to profit and delivered 460 aircraft in the first 10 months of the year, Boeing remains in the red and has supplied just 268 planes

November 13, 2021 / 13:52 IST
A320neo jets (Image Source: Wikimedia Commons)

The aviation industry is slowly recovering from last year's COVID-induced downturn, but European aircraft maker Airbus is having a smoother ride than American rival Boeing, which has endured a series of crises.

The world's dominant aerospace companies will seek new business as they attend the five-day Dubai air show on Sunday, the industry's first major event since the pandemic started last year.

But while Airbus has returned to profit and delivered 460 aircraft in the first 10 months of the year, Boeing remains in the red and has supplied just 268 planes.

Boeing's 737 MAX returned to the skies last year after the entire fleet was grounded for 20 months following two crashes — in Ethiopia and Indonesia — that left 346 people dead.

Almost 370 of the planes remain in inventory and Boeing chief executive David Calhoun has said that it will take two years to sell them all.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The 737 MAX has also yet to be re-certified in China, a major market for aircraft makers. Boeing's production plans will depend on access to the Chinese market, Calhoun says.

The 787 Dreamliner has had its share of problems which is estimated to have cost the company $1 billion.

The company halted deliveries of the 787 in May following a series of issues with the plane — the second suspension in the past year.

Boeing announced in July that it had spotted additional problems near the nose of the plane and was working to fix them.

A delay for the first deliveries of its new wide-body 777X plane — which were pushed back from 2022 to late 2023 — is costing the company $6.5 billion.

"There's been so many problems that it's very difficult to say they're over," Richard Aboulafia, analyst at aerospace consultancy Teal Group, told AFP.

COVID-19 cuts long-haul flights

Covid has also hit Boeing's strong point — long-haul aircraft — as international travel has been curbed by pandemic restrictions, said Remy Bonnery, an analyst at Archery Strategy Consulting.

International air traffic is only expected to return to pre-pandemic levels between 2023 and 2025.

Domestic air travel, meanwhile, is doing better — which benefits Airbus and its A320 family of narrow-body aircraft.

Airbus will display its latest single-aisle plane, the A321neo, in Dubai.

The company aims to release the long-range version of the aircraft in 2023, the A321XLR, which can fly for 10 hours — a feat only achieved by bigger planes until now.

"Airbus is alone in the single-aisle, long-haul market," said Bonnery at Archery Strategy Consulting.

"The next 10 years, we will have more plane deliveries by Airbus than Boeing," he said.

Staunch the bleeding

Boeing decided last year to hold off on launching its New Midsize Aircraft (NMA) project. The plan was to deliver by 2025 an aircraft that could transport up to 275 passengers nearly 9,000 kilometres (5,600 miles).

The US company "is losing 10 points of market share, largely due to the A321neo. Losing 10 points of market share is a road towards being a marginal player," Aboulafia said.

Boeing would have to launch a new plane to claw back market share, said Michel Merluzeau, an analyst at AIR consultancy.

"It must really staunch the bleeding against Airbus," Merluzeau said.

Regaining a place on the market "is very complicated and very expensive" — at least $15 billion — he said.

Boeing's debt has increased five-fold in less than three years to $62 billion.

It would be hard for Boeing to get a new plane out before 2028-2029, according to Merluzeau.

Calhoun indicated in October that the company has put a team together to design a new plane and production system.

AFP
first published: Nov 13, 2021 01:52 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347